Effects of macitentan: A Synthesis of Findings from 28 Studies

  1. Home
  2. Effects of macitentan
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of macitentan: A Synthesis of Findings from 28 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of macitentan: A Synthesis of Findings from 28 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Macitentan, a dual endothelin receptor antagonist, has shown promising effects in various studies. 8 demonstrated that Macitentan reduced right ventricular (RV) systolic pressure and pulmonary artery remodeling while increasing RV ejection fraction in a rat model of pulmonary hypertension. 18 found that Macitentan effectively inhibited human cytomegalovirus (HCMV) infection, suggesting potential antiviral properties. 15 investigated the impact of Macitentan on antitumor immune responses, revealing its ability to enhance CD8+ T cell-mediated tumor killing by suppressing tumor-derived extracellular vesicle PD-L1 secretion. These findings highlight the potential benefits of Macitentan in various medical contexts, including pulmonary hypertension, viral infections, and cancer therapy.

Benefits and Risks

Benefits Summary

Macitentan has been shown to improve heart function and reduce the severity of pulmonary hypertension in animal models. 8 It may also have antiviral properties and could potentially enhance the effectiveness of cancer treatments. 18 15

Risks Summary

Macitentan may cause side effects such as anemia, headaches, and bronchitis. 4 It can interact with other medications and may have a negative impact on liver function. 14 It is also contraindicated in pregnancy. 18

Comparison Between Studies

Commonalities

Many studies indicate that Macitentan exhibits beneficial effects in treating pulmonary hypertension and related conditions. 8 These studies consistently suggest that Macitentan may improve heart function, reduce pulmonary vascular resistance, and enhance overall health outcomes in individuals with pulmonary hypertension.

Differences

The studies vary in terms of the specific research methods used, patient populations, and outcomes assessed. 18 15 Some studies focus on the antiviral effects of Macitentan, while others explore its potential role in enhancing cancer therapy. 18 15 This diversity in research approaches provides a broader understanding of Macitentan's potential therapeutic applications.

Consistency and Contradictions in Results

While the majority of studies demonstrate positive effects of Macitentan, there are inconsistencies regarding its safety profile. 4 Some studies have linked Macitentan to an increased risk of anemia, headaches, and bronchitis. 4 However, other studies have reported Macitentan to be safe and well-tolerated. 11 Further investigation into the safety and long-term effects of Macitentan is crucial to ensure its safe and effective use in clinical practice.

Considerations for Real-World Applications

Macitentan holds promise as a therapeutic agent for pulmonary hypertension and potentially other medical conditions. 11 However, it's important to be aware of potential side effects such as anemia, headaches, and bronchitis. 4 Careful monitoring and consultation with a healthcare professional are essential when considering Macitentan treatment.

Limitations of Current Research

Research on Macitentan is still ongoing, and more studies are needed to fully understand its long-term effects and safety profile. 4 Further investigation into potential drug interactions and the impact of Macitentan on specific patient populations is also necessary.

Future Research Directions

Future research should focus on investigating the long-term safety and efficacy of Macitentan in various populations. 4 Additional studies are needed to determine the optimal dosing and treatment regimens for different patient groups. 18 15

Conclusion

Macitentan has shown promising potential as a therapeutic agent for pulmonary hypertension and may have broader applications in viral infections and cancer treatment. 11 3 However, it's important to be aware of potential side effects. 4 It's crucial to consult with a healthcare professional to determine if Macitentan is suitable for your individual needs and to manage any potential risks. 14 Further research is ongoing to enhance our understanding of Macitentan's effects and optimize its use in clinical practice.

Literature analysis of 28 papers
Positive Content
24
Neutral Content
2
Negative Content
2
Article Type
1
5
3
5
26
1.

Comparative Treatment Persistence and Adherence to Endothelin Receptor Antagonists Among Patients with Pulmonary Arterial Hypertension in Japan: A Real-World Administrative Claims Database Study.

Author: OmuraJunichi, MakanjiYogeshwar, TanabeNobuhiro, YuDae Young, TanJin Yu, LimSooyeol, KouhkamariMahsa H, CasorsoJeremy, WuDavid Bin-Chia, BloomfieldPaul

Persistence

This study evaluated the persistence of endothelin receptor antagonists (ERAs) for pulmonary arterial hypertension in Japan before and after macitentan approval. The study found that the use of ERAs increased after macitentan approval.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

2.

Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Author: QinJinlv, WangGuizuo, HanDong

Improved 6MWD
Improved cardiac index
PH treatment
Reduced NT-proBNP
Reduced PVR
Reduced mPAP

This meta-analysis found that macitentan significantly improved various parameters in patients with pulmonary hypertension (PH), including 6-minute walk distance, pulmonary vascular resistance, mean pulmonary artery pressure, N-terminal pro-brain natriuretic peptide, and cardiac index. Macitentan is a promising treatment for PH, but further studies are needed to validate its effectiveness.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

4.

Long-term safety of macitentan in patients with pulmonary hypertension: A meta-analysis of randomised controlled trials.

Author: WangGuizuo, QinJinlv, HanDong

Anemia (macitentan)
Bronchitis (macitentan)
Headache (macitentan)

Macitentan is safe for long-term use in patients with pulmonary hypertension, although it may increase the risk of anemia, headache, and bronchitis.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

5.

Macitentan in the Young-Mid-term Outcomes of Patients with Pulmonary Hypertensive Vascular Disease treated in a Pediatric Tertiary Care Center.

Author: AlbinniSulaima, HenoJulian, PavoImre, KitzmuellerErwin, MarxManfred, Michel-BehnkeIna

PH treatment

This prospective study investigated the mid- and long-term effects of macitentan, a safe and effective drug for adult pulmonary hypertension (PH), in children with advanced pulmonary hypertensive vascular disease.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

6.

Cost-Effectiveness Analysis of Macitentan in Comparison With Bosentan in the Treatment of Pulmonary Arterial Hypertension in Iran.

Author: EkhlasiMahna, SheikhiShiva, MajdZahra Karimi, PeiravianFarzad, YousefiNazila

improved life expectancy
improved quality of life
improved symptoms

This study evaluated the cost-utility of macitentan compared with bosentan for treating pulmonary arterial hypertension (PAH) in Iran.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

7.

Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis.

Author: LiJie, YangZu-Yuan, WangShang, YuanPing, ZhaoQin-Hua, GongSu-Gang, QiuHong-Ling, LuoCi-Jun, LiHui-Ting, ZhangRui, WuWen-Hui, LiuJin-Ming, WangLan, LiuShan-Shan, JiangRong

Improved PAH
Unknown impact

This systematic review and meta-analysis aimed to assess the efficacy and safety of switching from bosentan or ambrisentan to macitentan in patients with pulmonary arterial hypertension (PAH). The review found limited evidence on this specific treatment switch.

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

9.

Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study.

Author: Di ScalaLilla, BacchiMarisa, BayerBjørn, TurricchiaStefano

Survival improvement

This analysis attempts to adjust for the confounding effects of treatment switching in a large clinical trial that evaluated the effects of macitentan in patients with pulmonary arterial hypertension.

Clinical StudyResearch involving human participants to assess the safety, efficacy, and effects of an intervention/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

10.

Chronic intermittent hypoxia, a hallmark of obstructive sleep apnea, promotes 4T1 breast cancer development through endothelin-1 receptors.

Author: MinovesMélanie, KotzkiSylvain, Hazane-PuchFlorence, LemariéEmeline, BouyonSophie, VollaireJulien, GonthierBrigitte, PépinJean-Louis, JosserandVéronique, Briançon-MarjolletAnne, Godin-RibuotDiane

Breast cancer prevention
Intermittent hypoxia
OSA

This study investigated the impact of intermittent hypoxia (IH) on breast cancer development in vitro and in vivo. IH is a hallmark of obstructive sleep apnea (OSA), a common sleep disorder. The researchers found that IH promoted breast cancer growth and malignancy in vitro and in vivo and that this effect was reversed by a dual endothelin receptor antagonist.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension.

Author: SouzaRogério, DelcroixMarion, GaliéNazzareno, JansaPavel, MehtaSanjay, PulidoTomás, RubinLewis, SastryB K S, SimonneauGérald, SitbonOlivier, TorbickiAdam, BoyanovaNeli, ChamitavaLiliya, SteinClaudia, ChannickRichard N

Morbidity/mortality reduction

Macitentan is a medication used to treat pulmonary arterial hypertension, a rare disease that affects the arteries in the lungs. This study examines the long-term safety and tolerability of macitentan in patients with pulmonary arterial hypertension.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

Porto-pulmonary arterial hypertension: Translation of pathophysiological concepts to the bedside.

Author: MazzolaMatteo, MadonnaRosalinda, BadagliaccaRoberto, CaterinaRaffaele De

Hemodynamic benefit in PoPAH
Therapeutic barriers
Worse survival

Porto-pulmonary arterial hypertension (PoPAH) is a form of pulmonary arterial hypertension (PAH) affecting patients with cirrhosis. PoPAH patients have a worse survival than those with other PAH forms despite favorable hemodynamics. This review discusses the pathophysiology and management of PoPAH and reports a case vignette of a patient with PoPAH due to hepatorenal polycystic disease.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

14.

Effects of Concomitant Administration of PXR Ligand Drugs on the Anticoagulant Effects of Warfarin.

Author: MitoAyane, HironoKeiichi, IdeHaruka, OzawaSayaka, IchidaFukiko, TaguchiMasato

Warfarin anticoagulation
Drug-drug interactions

Rifampicin and bosentan, potent pregnane X receptor (PXR) ligands, can reduce the anticoagulant effects of warfarin. This case report and longitudinal study demonstrate that withdrawing or switching bosentan treatment can lead to recovery or decrease in warfarin anticoagulant effects, respectively. The study highlights the importance of long-term monitoring for drug-drug interactions when switching between bosentan and macitentan.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

15.

Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.

Author: LeeChan-Hyeong, BaeJu-Hyun, ChoeEun-Ji, ParkJu-Mi, ParkSeong-Sik, ChoHee Jin, SongByoung-Joon, BaekMoon-Chang

Antitumor responses
Improved response to PD-1/PD-L1 blockade

This study identified macitentan, an FDA-approved drug, as a potential enhancer of antitumor responses by suppressing tumor-derived EV PD-L1, which can inhibit the effectiveness of immune checkpoint blockade drugs.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

22.

Effects of sildenafil on right ventricle remodelling in Portopulmonary hypertension.

Author: RossiRosario, TalaricoMarisa, SchepisFilippo, CoppiFrancesca, SguraFabio Alfredo, MonopoliDaniel Enrique, MiniciRoberto, BorianiGiuseppe

PoPH treatment
RV remodeling
sildenafil

Sildenafil treatment significantly improved right ventricle performance and conditioned reverse remodeling in patients with portopulmonary hypertension.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

23.

Repurposing macitentan with nanoparticle modulates tumor microenvironment to potentiate immune checkpoint blockade.

Author: SonSoyoung, ShinJung Min, ShinSol, KimChan Ho, LeeJae Ah, KoHyewon, LeeEun Sook, JungJae Min, KimJeongyun, ParkJae Hyung

Antitumor effect

Macitentan, a dual endothelin receptor antagonist, can be repurposed to modulate the tumor microenvironment (TME) and enhance immune checkpoint therapy (ICT) efficacy. Macitentan-loaded nanoparticles prevent fibrosis, attenuate exosome biogenesis, and modulate T cell subsets in the TME, improving antitumor responses.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

24.

Adolescents and adults with Fontan circulation: insights from the PREpArE-Fontan registry.

Author: SøndergaardLars, AboulhosnJamil, d'UdekemYves, FaureCéline, FranklinWayne J, HagerAlfred, KimYuli Y, Muros-Le RouzicErwan, RosenbergDaniel, SchwerzmannMarkus, CliftPaul

Fontan failure

This study describes a cohort of patients with stable Fontan circulation who could potentially participate in a clinical trial investigating macitentan, an endothelin receptor antagonist. The study found that 53.4% of patients met the eligibility criteria and identified early signs of Fontan failure, even in stable patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

25.

Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension.

Author: AngeliFabio, VerdecchiaPaolo, ReboldiGianpaolo

Resistant hypertension treatment

Aprocitentan is an orally active, dual endothelin-1 (ET-1) receptor antagonist currently under investigation for the treatment of resistant hypertension. The data suggest that aprocitentan has the potential to expand the antihypertensive arsenal and provide broader cardiovascular protection.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

27.

[Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia].

Author: ShmaltsA A, GorbachevskyS V

PAH treatment

This review discusses the use of initial combination therapy with PAH-specific drugs in patients with pulmonary arterial hypertension (PAH). Combination therapy may be beneficial in both high-risk and low-risk patients, but further clinical trials are needed.

Classical ArticleA research paper that has had a significant impact on a specific field. Cited as fundamental research.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : Russian

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.